Intervention

TCHP

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting2

Common conditions3

Lead sponsors shown3

Clinical trials

3 shown

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast CancerNCT05256745 · 2023-06-06

RECRUITING

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast CancerNCT04281641 · 2020-04-21

RECRUITING

TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast CancerNCT04094896 · 2019-09-17

UNKNOWN

Common conditions

HER2-positive Breast Cancer2 Cancer Related Cognitive Decline1 Non-metastatic Breast Cancer1

Leading sponsors

Fudan University 1 Georgetown University 1 Guangdong Provincial People's Hospital 1

Trial status mix

RECRUITING2

UNKNOWN1

Phase mix

PHASE22

NA1

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.